TransMedics Group Inc. (TMDX) Stock
NASDAQTMDX has an Alpha Score of 42 out of 100 (weak), computed on Nov 3, 2026 from 3 of 4 sub-scores. 3 of the hedge funds AlphaScala tracks reported TMDX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $37.12M. Company insiders reported 1 open-market buy and 0 sales on SEC Form 4 in the 90 days to Nov 2, 2026. Its trailing P/E ratio is 15.0 and its net margin 22.7% (key statistics as of Oct 31, 2026).
What is TMDX's Alpha Score?
How it works →Alpha Score of 42 reflects weak overall profile with poor momentum, moderate value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 3, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own TMDX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 559K | $37.12M | +807% |
| Millennium Management Israel Englander | 248K | $16.49M | -19% |
| Point72 Steve Cohen | 193K | $12.79M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are TransMedics Group Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 11, 26 | Weill David | Director | BUY | 1.3K | $109K |
| Mar 4, 26 | Weill David | Director | SELL | 3.6K | $524K |
| Mar 4, 26 | Hernandez Gerardo | Chief Financial Officer | SELL | 1.3K | $195K |
| Mar 4, 26 | Hernandez Gerardo | Chief Financial Officer | SELL | 5.9K | $870K |
| Mar 4, 26 | Lovell Stephanie | Director | SELL | 1.2K | $178K |
| Mar 2, 26 | Ranganath Anil P. | See remarks | SELL | 864 | $120K |
| Mar 2, 26 | Hernandez Gerardo | Chief Financial Officer | SELL | 375 | $52K |
| Mar 2, 26 | Corcoran Nicholas | See remarks | SELL | 3.0K | $413K |
| Dec 4, 25 | Hernandez Gerardo | Chief Financial Officer | SELL | 920 | $128K |
| Dec 3, 25 | Weill David | Director | SELL | 5.0K | $693K |
SEC Form 4 filings as of Nov 2, 2026
See cluster-buy signals across all tickers →What are TMDX's key statistics?
Key statistics as of Oct 31, 2026
How does TMDX's valuation compare with the Healthcare sector?
| Metric | TMDX | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 15.0 | 27.2 | 99 |
| Net margin | 22.69% | 4.85% | 143 |
| Return on equity | 32.97% | 6.68% | 162 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 3, 2026). P/E excludes loss-making companies.
TMDX price chart
Powered by TradingViewWhat does TransMedics Group Inc. do?
TransMedics Group Inc. is a commercial-stage medical technology company focused on advancing organ transplant therapy for patients with end-stage organ failure. It develops and commercializes the Organ Care System (OCS), a portable platform that preserves, optimizes, and monitors donor organs in near-physiologic conditions outside the body, overcoming limitations of traditional cold storage methods. The OCS supports multiple organ types, enabling improved transplant outcomes through real-time assessment and maintenance during transport. TransMedics Group Inc. operates in the health technology sector, specifically medical specialties, serving transplant centers and healthcare providers to expand access to viable organs. The company enhances organ utilization rates and logistics, including aviation partnerships for nationwide transport networks. Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics Group Inc. plays a critical role in transforming solid organ transplantation by integrating innovative perfusion technology with comprehensive organ recovery services.